Adocia has announced positive results from a phase IIa clinical trial evaluating its innovative ultra-fast formulation of insulin Lispro in comparison to Eli Lilly’s Humalog® commercial insulin.

Superior long term glycemic control in people using Metformin or with HbA1c below 8.5% Superior glucose control throughout the day and after each meal for the whole population. BioChaperone® Lispro is ...

Adocia has announced positive final results for the first clinical trial on its innovative formulation combining insulin analog glargine (Lantus®, Sanofi), the gold standard basal insulin, with a ...

LYON, France--(BUSINESS WIRE)--Regulatory News: Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative ...

Introduction to Adocia’s proprietary BioChaperone ® technology platform, by You-Ping Chan Current mealtime insulin treatment paradigm for diabetes and limitations by Tim Heise Ultra-Rapid insulin BC ...

Adocia announces preliminary positive clinical results for its combination of long-acting insulin Glargine and fast-acting insulin analog Lispro, Biochaperone(R) Combo Adocia's BioChaperone Combo is ...

Adocia SA is looking to further apply its Biochaperone formulation technology to metabolic disorders, Olivier Soula, Adocia co-founder and CEO told BioWorld, the firm having recently gained positive ...

LYON, France--(BUSINESS WIRE)-- Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of ...

Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of ...

The virtual event titled "Advancing Mealtime Insulin Therapy: Phase 3 Results for BC Lispro in Type 2 Diabetes" will take place on Tuesday, June 16, 2026, at 10:00 a.m. EST / 4:00 p.m. CEST The ...

LYON, France--(BUSINESS WIRE)-- Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of ...